Pfizer Moves to Acquire Seagen; Apple TV+ Revenue Poised to Jump; Netflix Subscription Fees

Pfizer Moves To Acquire Seagen; Apple Tv+ Revenue Poised To Jump; Netflix Subscription Fees

In our weekly round-up of the top charts and market-moving analyst insights: Seagen is expected to show sharp sales growth as Pfizer moves to acquire the biotech innovator; Apple TV+ revenue is estimated to double by 2024; Netflix is expected to collect more than $20/month in subscriber revenue per U.S. and Canadian subscriber by 2027; and Softbank’s Arm may grow sales more than 70% as Softbank explores an IPO for the chip designer.

Seagen: Analysts See Healthy Sales Growth as Pfizer Makes $43B Acquisition

Analysts see Seagen (SGEN) tripling sales by 2028, according to Visible Alpha consensus, as the company accepted a $43B buyout offer by Pfizer (PFE). Merck offered $40B for the company in 2022, but the offer was rejected.

Seagen SGEN

Apple TV+ Revenue Estimated to Double by 2024, Say Analysts

According to Visible Alpha consensus, analysts believe Apple TV+ revenue will double by 2024  as the service benefits in part from hit content such as Shrinking and Ted Lasso, which had its Season 3 premiere on March 15.

AAPL apple TV streaming revenue v

Netflix Estimated to Collect >$20/Month Per UCAN Subscriber by 2027, Say Analysts

Analysts believe Netflix’s (NFLX) average revenue per U.S. and Canadian (UCAN) subscriber will surpass $20/month by 2027, according to Visible Alpha consensus.

NFLX ARPU by region

Analysts Believe Arm Will Grow Sales >70% Through 2025 as Softbank Reportedly Explores IPO

Analysts are forecasting over 70% sales growth for Softbank’s Arm through 2025, according to Visible Alpha consensus. Softbank is reportedly exploring an IPO for Arm, a British semiconductor design company, in what could be the largest launch in U.S. markets this year.

Softbank ARM


Tags: , ,